Eisai Co., Ltd. (“the Company”) and its affiliates (collectively referred to as “the Group”)
List of Group Companies(As of March 31, 2021)
Company Name

Location

Share Capital

Description ofOperations (*1)

VotingRights(*2)

Relationship

Note(Consolidated Subsidiaries)
Unit=million
The Company
commissions
pharmaceutical R&D
The Company
commissions
pharmaceutical logistics
The Company
commissions a part ofmanagement and otherfunctions related to R&D
The Company purchases
business support services,etc.
The Company
commissions
pharmaceutical R&D andproduction / purchases
pharmaceutical products

KAN ResearchInstitute, Inc.

Kobe, Japan70JPYPharmaceutical R&D

100.00%Eisai Distribution
Co., Ltd.

Kanagawa, Japan

60JPY

Pharmaceuticallogistics

100.00%Eisai R&D
Management Co.,Ltd.

Tokyo, Japan

16JPY

Management ofpharmaceutical R&D

100.00%Sunplanet Co.,Ltd.

Tokyo, Japan

455

JPY

Business support
services, etc.

85.30%EA Pharma Co.,Ltd.

Tokyo, Japan

9,145

JPY

Pharmaceutical R&D/ production / sales

60.00%

Eisai Corporationof North America

New Jersey,
USA

USD

Americas holding
company

100.00%Eisai Inc.

New Jersey,
USA

151,600

USD

Pharmaceutical R&D/ production / sales

100.00%(100.00%)

H3 Biomedicine
Inc.

Massachusetts, USA8USD

Pharmaceutical R&D

100.00%(100.00%)

Eisai Innovation,Inc.

Massachusetts, USA1

USD

Management ofpharmaceuticalinvestment

100.00%(100.00%)

Eisai Ltd.

Ontario, Canada

30,000CAD

Pharmaceutical sales

100.00%(100.00%)-Eisai China
Holdings Ltd.

Jiangsu, China

664,465

RMB

Chineseheadquarters /holding company

100.00%(100.00%)-*3

Eisai China Inc.

Jiangsu, China

576,125

RMB

Pharmaceuticalproduction / sales

100.00%(100.00%)

The Company sells
pharmaceutical products
and API*3

Eisai (Suzhou)
Trading Co., Ltd.

Jiangsu, China

70,000RMBPharmaceutical sales

100.00%(100.00%)

The Company sells
pharmaceutical products

Eisai (Liaoning)
PharmaceuticalCo., Ltd.

Liaoning, China

50,000

RMB

Pharmaceuticalproduction / sales

100.00%(100.00%)-Eisai Europe Ltd.

Hertfordshire,UK

184,138

GBP

Europe headquarters/ holding company,
pharmaceutical sales

100.00%Eisai Ltd.

Hertfordshire,UK

46,009GBP

Pharmaceutical R&D/ sales100.00%(100.00%)

Eisai
Manufacturing Ltd.

Hertfordshire,UK

38,807

GBP

Pharmaceutical R&D/ production

100.00%(100.00%)

Eisai GmbH

Frankfurt,
Germany

7,669

EUR

Pharmaceutical sales

100.00%(100.00%)-

Eisai S.A.S.

Paris, France

19,500EUR

Pharmaceutical sales

100.00%(100.00%)-

Eisai B.V.

Amsterdam,
Netherlands

540

EUR

Pharmaceutical sales

100.00%(100.00%)-

Eisai
Farmacéutica S.A.

Madrid, Spain

4,000

EUR

Pharmaceutical sales

100.00%(100.00%)-

Eisai S.r.l.

Milan, Italy

3,500

EUR

Pharmaceutical sales

100.00%(100.00%)-

Eisai Pharma AG

Zurich,Switzerland

3,000

CHF

Pharmaceutical sales

100.00%(100.00%)-

Eisai AB

Stockholm,
Sweden10,000SEK

Pharmaceutical sales

100.00%(100.00%)-*3

Unit=thousand
2,266,700

The Company
commissions
pharmaceutical R&D andproduction / sells
pharmaceutical products
and APIThe Company
commissions
pharmaceutical R&D
The Company
commissions managementof investment in the U.S.
and Europe

The Company
commissions management
and administration ofpharmaceutical business
The Company
commissions
pharmaceutical R&D
The Company sells
pharmaceutical products
and API / is commissioned
pharmaceutical R&D

*3*3
*5*3

*3*3

Company Name

Location

Share Capital

Description ofOperations (*1)

VotingRights(*2)-Relationship

Note

Unit= thousand
Eisai Farmacêutica,
Unipessoal Lda.

1,250

EUR

Pharmaceutical sales

2,001

EUR

Pharmaceutical salesEisai GesmbH

Lisbon,Portugal
Brussels,
Belgium
Vienna,Austria

2,000

EUR

Pharmaceutical sales

100.00%(100.00%)
100.00%(100.00%)
100.00%(100.00%)

Limited Liability
Company EisaiMoscow,
Russia4,000RUB

Pharmaceutical sales

100.00%(100.00%)-Eisai Asia Regional
Services Pte. Ltd.

Singapore

34,469

SGD

Asia holding company

100.00%-Eisai (Singapore)
Pte. Ltd.

Singapore

300

SGD

Pharmaceutical sales

100.00%(100.00%)

The Company sells
pharmaceutical products

Eisai ClinicalResearch
Singapore Pte. Ltd.

Singapore

10SGD

Pharmaceutical R&D

100.00%(100.00%)

The Company commissions
pharmaceutical R&D

Eisai Taiwan Inc.

Taipei,Taiwan270,000

TWD

Pharmaceutical sales

100.00%

The Company sells
pharmaceutical products

Eisai (Thailand)Marketing Co., Ltd.

Bangkok,Thailand

103,000

THB

Pharmaceutical sales

100.00%(100.00%)

The Company sells
pharmaceutical products

PT Eisai Indonesia

Jakarta,Indonesia

1,630,000

IDR

Pharmaceuticalproduction / sales

100.00%

The Company sells
pharmaceutical products andAPI

Eisai (Malaysia)
Sdn. Bhd.

Petaling
Jaya,
Malaysia

470

MYR

Pharmaceutical sales

100.00%(5.74%)The Company sells
pharmaceutical products

HI-Eisai
Pharmaceutical Inc.

Manila,Philippines

97,000PHP

Pharmaceutical sales

50.00%(1.45%)The Company sells
pharmaceutical products

Eisai (Hong Kong)
Co., Ltd.

Hong Kong

500

HKD

Pharmaceutical sales

100.00%(10.00%)

The Company sells
pharmaceutical products

Eisai Korea Inc.

Seoul,South Korea

3,512,000

KRW

Pharmaceutical sales

100.00%

Eisai
Pharmaceuticals
India Pvt. Ltd.

AndhraPradesh,India

2,708,324

INR

Pharmaceutical R&D /production / sales

100.00%(11.08%)The Company sells
pharmaceutical products
The Company commissions
pharmaceutical R&D andproduction / sells API /purchases pharmaceuticalproductsEisai Australia Pty.
Ltd.

Sydney,Australia

4,000

AUD

Pharmaceutical sales

100.00%-Eisai LaboratóriosLtda.

São Paulo,
Brazil

87,899BRL

Pharmaceutical sales

100.00%(100.00%)-

Eisai Laboratorios
S. de R.L. de C.V.

Mexico City,
Mexico3

MXN

Pharmaceutical sales

100.00%(100.00%)-

Eisai New Zealand
Ltd.

Auckland,
New Zealand

2,050

NZD

Pharmaceuticalbusiness

100.00%(100.00%)-

Eisai Vietnam Co.,Ltd.

Ho Chi Minh,
Viet Nam

20,781,000

VND

Pharmaceuticalbusiness100.00%------

Eisai SA/NV

Other—2
companies--*4*3*6(Associated Companies Accounted for Using the Equity Method)
Unit=million
Bracco-Eisai Co.,Ltd.

Tokyo, Japan

340

JPY

Unlimit Health
LimitedShanghai,
China

30

RMB

Contrast media
imports / production /sales
Pharmaceuticalbusiness

49.00%
49.00%(49.00%)

The Company purchases
pharmaceutical products-*7

Notes:*1. "Description of Operations" indicates the segment applicable to the respective entity.
*2. Voting rights (%): Figures in parentheses show percentage indirectly owned by the Company.
*3. Significant subsidiaries.
*4. HI-Eisai Pharmaceutical Inc. is considered to be a consolidated subsidiary as the Company holds effective control over its operation eventhough the Company's voting rights do not exceed 50%.
*5. Eisai Inc. is the only subsidiary whose revenue to external customers exceeds 10% of consolidated revenue reported in the consolidated
financial statements for the fiscal year ended March 31, 2021. Key financial results (in Japanese yen) of Eisai Inc. are as follows:
Revenue¥215,073 mil.
Operating Profit¥6,762 mil.
Profit for the year
¥6,452 mil.
Total Equity¥284,747 mil.
Total Assets¥385,400 mil.
*6. In September 2020, the Company established Eisai Vietnam Co., Ltd.
*7. In October 2020, Eisai China Holdings Ltd. and Suqian Jingdong Tianning Jiankang Technology Co., Ltd. established Unlimit Health Limited.